Goldman doesn't see "significant downside" to shares of Merck (MRK +0.5%), but notes that...

Goldman doesn't see "significant downside" to shares of Merck (MRK +0.5%), but notes that today's news (previous) marks "another pipeline setback in a year that has seen a tredaptive failure [and an] odanacatib delay." Analyst Jami Rubin has now pushed his suvorexant "launch assumption from 2014 out to 2015."

From other sites
Comments (1)
  • bricius
    , contributor
    Comments (52) | Send Message
    The market may react negatively, but I don't see it the same light. Plan for launching may be delayed because of acceptance of the low dose only, but it is still an acceptance and not flat out rejection. MRK finally got something novel from its pipeline, it's meager but better than nothing. Let's hope this company is healing after 10 year of so so mediocrity in R&D. Let's hope for odacatinib, anti-PD1 etc. There is a new boss in R&D, let's hope for real change and serious catch-up, both in HR and program content.
    1 Jul 2013, 05:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs